{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:04:01Z","timestamp":1768824241611,"version":"3.49.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19lk0201100"],"award-info":[{"award-number":["JP19lk0201100"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19gk0110041"],"award-info":[{"award-number":["JP19gk0110041"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Japanese Ministry of Health, Labor, and Welfare","award":["20FC1053"],"award-info":[{"award-number":["20FC1053"]}]},{"name":"The Department of Pediatrics, Perinatal and Maternal Medicine","award":["91AA192328"],"award-info":[{"award-number":["91AA192328"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12185-022-03389-7","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T15:02:58Z","timestamp":1654700578000},"page":"7-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Conditioning regimens for inborn errors of immunity: current perspectives and future strategies"],"prefix":"10.1007","volume":"116","author":[{"given":"Akira","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-8403","authenticated-orcid":false,"given":"Kohsuke","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Morio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"issue":"1","key":"3389_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","volume":"40","author":"A Bousfiha","year":"2020","unstructured":"Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol. 2020;40(1):66\u201381.","journal-title":"J Clin Immunol"},{"issue":"7583","key":"3389_CR2","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","volume":"292","author":"R Gatti","year":"1968","unstructured":"Gatti R, Meuwissen H, Allen H, Hong R, Good R. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968;292(7583):1366\u20139.","journal-title":"Lancet"},{"issue":"9","key":"3389_CR3","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","volume":"56","author":"AC Lankester","year":"2021","unstructured":"Lankester AC, Albert MH, Booth C, Gennery AR, Gungor T, Honig M, et al. EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity. Bone Marrow Transplant. 2021;56(9):2052\u201362.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"3389_CR4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/ped.12325","volume":"56","author":"A Hoshino","year":"2014","unstructured":"Hoshino A, Imai K, Ohshima Y, Yasutomi M, Kasai M, Terai M, et al. Pneumothorax in patients with severe combined immunodeficiency. Pediatr Int. 2014;56(4):510\u20134.","journal-title":"Pediatr Int"},{"issue":"10","key":"3389_CR5","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/ped.13070","volume":"58","author":"T Sato","year":"2016","unstructured":"Sato T, Okano T, Tanaka-Kubota M, Kimura S, Miyamoto S, Ono S, et al. Novel compound heterozygous mutations in a Japanese girl with Janus kinase 3 deficiency. Pediatr Int. 2016;58(10):1076\u201380.","journal-title":"Pediatr Int"},{"key":"3389_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fped.2019.00461","volume":"7","author":"S Bakhtiar","year":"2019","unstructured":"Bakhtiar S, Fekadu J, Seidel MG, Gambineri E. Allogeneic hematopoietic stem cell transplantation for congenital immune dysregulatory disorders. Front Pediatr. 2019;7:461.","journal-title":"Front Pediatr"},{"issue":"1","key":"3389_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1182\/blood-2007-03-076679","volume":"111","author":"H Ozsahin","year":"2008","unstructured":"Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, Schulz A, Thrasher AJ, Mazzolari E, et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott\u2013Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood. 2008;111(1):439\u201345.","journal-title":"Blood"},{"issue":"4","key":"3389_CR8","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jaci.2016.01.053","volume":"138","author":"K Rao","year":"2016","unstructured":"Rao K, Adams S, Qasim W, Allwood Z, Worth A, Silva J, et al. Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen. J Allergy Clin Immunol. 2016;138(4):1152\u201360.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3389_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10875-017-0375-9","volume":"37","author":"M Nagasawa","year":"2017","unstructured":"Nagasawa M, Ohkawa T, Takagi M, Imai K, Morio T. A Stable mixed chimera after SCT with RIC in an infant with IkappaBalpha hypermorphic mutation. J Clin Immunol. 2017;37(5):413\u20134.","journal-title":"J Clin Immunol"},{"issue":"4","key":"3389_CR10","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaci.2016.07.039","volume":"139","author":"MT de la Morena","year":"2017","unstructured":"de la Morena MT, Leonard D, Torgerson TR, Cabral-Marques O, Slatter M, Aghamohammadi A, et al. Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation. J Allergy Clin Immunol. 2017;139(4):1282\u201392.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3389_CR11","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jaci.2018.12.1010","volume":"143","author":"F Ferrua","year":"2019","unstructured":"Ferrua F, Galimberti S, Courteille V, Slatter MA, Booth C, Moshous D, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT\/ESID-IEWP-SCETIDE-PIDTC study. J Allergy Clin Immunol. 2019;143(6):2238\u201353.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"3389_CR12","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jaci.2015.02.020","volume":"136","author":"K Mitsui-Sekinaka","year":"2015","unstructured":"Mitsui-Sekinaka K, Imai K, Sato H, Tomizawa D, Kajiwara M, Nagasawa M, et al. Clinical features and hematopoietic stem cell transplantations for CD40 ligand deficiency in Japan. J Allergy Clin Immunol. 2015;136(4):1018\u201324.","journal-title":"J Allergy Clin Immunol"},{"issue":"9357","key":"3389_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0140-6736(03)12513-5","volume":"361","author":"C Antoine","year":"2003","unstructured":"Antoine C, M\u00fcller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968\u201399. Lancet. 2003;361(9357):553\u201360.","journal-title":"Lancet"},{"issue":"5","key":"3389_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bmt.1705273","volume":"37","author":"Y Tsuji","year":"2006","unstructured":"Tsuji Y, Imai K, Kajiwara M, Aoki Y, Isoda T, Tomizawa D, et al. Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20\u00a0years experience of a single team. Bone Marrow Transplant. 2006;37(5):469\u201377.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"3389_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000225819","volume":"41","author":"HP Lohrmann","year":"1984","unstructured":"Lohrmann HP. The problem of permanent bone marrow damage after cytotoxic drug treatment. Oncology. 1984;41(3):180\u20134.","journal-title":"Oncology"},{"issue":"3","key":"3389_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/jcph.1027","volume":"58","author":"Y Ishiwata","year":"2018","unstructured":"Ishiwata Y, Nagata M, Tsuge K, Takahashi H, Suzuki S, Imai K, et al. Population pharmacokinetics of intravenous busulfan in Japanese pediatric patients with primary immunodeficiency diseases. J Clin Pharmacol. 2018;58(3):327\u201331.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"3389_CR17","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s10875-021-00966-z","volume":"41","author":"A Nishimura","year":"2021","unstructured":"Nishimura A, Aoki Y, Ishiwata Y, Ichimura T, Ueyama J, Kawahara Y, et al. Hematopoietic cell transplantation with reduced intensity conditioning using fludarabine\/busulfan or fludarabine\/melphalan for primary immunodeficiency diseases. J Clin Immunol. 2021;41(5):944\u201357.","journal-title":"J Clin Immunol"},{"issue":"2","key":"3389_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/bmt.2015.277","volume":"51","author":"AA Hamidieh","year":"2016","unstructured":"Hamidieh AA, Behfar M, Pourpak Z, Faghihi-Kashani S, Fazlollahi MR, Hosseini AS, et al. Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study. Bone Marrow Transplant. 2016;51(2):219\u201326.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"3389_CR19","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s10875-021-01112-5","volume":"41","author":"S Miyamoto","year":"2021","unstructured":"Miyamoto S, Umeda K, Kurata M, Nishimura A, Yanagimachi M, Ishimura M, et al. Hematopoietic cell transplantation for severe combined immunodeficiency patients: a Japanese retrospective study. J Clin Immunol. 2021;41(8):1865\u201377.","journal-title":"J Clin Immunol"},{"key":"3389_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10875-021-01199-w","volume":"42","author":"S Miyamoto","year":"2022","unstructured":"Miyamoto S, Umeda K, Kurata M, Yanagimachi M, Iguchi A, Sasahara Y, et al. Hematopoietic cell transplantation for inborn errors of immunity other than severe combined immunodeficiency in Japan: retrospective analysis for 1985\u20132016. J Clin Immunol. 2022;42:529\u201345.","journal-title":"J Clin Immunol"},{"issue":"23","key":"3389_CR21","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1182\/blood-2013-02-380105","volume":"122","author":"HB Gaspar","year":"2013","unstructured":"Gaspar HB, Qasim W, Davies EG, Rao K, Amrolia PJ, Veys P. How I treat severe combined immunodeficiency. Blood. 2013;122(23):3749\u201358.","journal-title":"Blood"},{"key":"3389_CR22","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.jaci.2021.10.017","volume":"149","author":"AC Lankester","year":"2022","unstructured":"Lankester AC, Neven B, Mahlaoui N, von Asmuth EGJ, Courteille V, Alligon M, et al. Hematopoietic cell transplantation in severe combined immunodeficiency: the SCETIDE 2006\u20132014 European cohort. J Allergy Clin Immunol. 2022;149:1744-1754.e8.","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"3389_CR23","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/blood-2018-03-840702","volume":"132","author":"E Haddad","year":"2018","unstructured":"Haddad E, Logan BR, Griffith LM, Buckley RH, Parrott RE, Prockop SE, et al. SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood. 2018;132(17):1737\u201349.","journal-title":"Blood"},{"issue":"4","key":"3389_CR24","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jaci.2013.01.047","volume":"131","author":"E Haddad","year":"2013","unstructured":"Haddad E, Leroy S, Buckley RH. B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? J Allergy Clin Immunol. 2013;131(4):994\u20131000.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3389_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1056\/NEJMoa1401177","volume":"371","author":"S-Y Pai","year":"2014","unstructured":"Pai S-Y, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, et al. Transplantation outcomes for severe combined immunodeficiency, 2000\u20132009. N Engl J Med. 2014;371(5):434\u201346.","journal-title":"N Engl J Med"},{"issue":"3","key":"3389_CR26","doi-asserted-by":"publisher","first-page":"602\u201310.e1\u201311","DOI":"10.1016\/j.jaci.2010.06.015","volume":"126","author":"AR Gennery","year":"2010","unstructured":"Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602-10.e1-11.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"3389_CR27","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s10875-021-01113-4","volume":"41","author":"H Hashem","year":"2021","unstructured":"Hashem H, Najjar R, Abu-Shanap M, Khattab E, Rihani R, Tbakhi A, et al. Haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide for children with non-malignant diseases. J Clin Immunol. 2021;41(8):1754\u201361.","journal-title":"J Clin Immunol"},{"issue":"1","key":"3389_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2019.08.018","volume":"26","author":"D Dimitrova","year":"2020","unstructured":"Dimitrova D, Gea-Banacloche J, Steinberg SM, Sadler JL, Hicks SN, Carroll E, et al. Prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases. Biol Blood Marrow Transplant. 2020;26(1):94\u2013106.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"3389_CR29","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/j.bbmt.2020.07.003","volume":"26","author":"JF Fernandes","year":"2020","unstructured":"Fernandes JF, Nichele S, Arcuri LJ, Ribeiro L, Zamperlini-Netto G, Loth G, et al. Outcomes after haploidentical stem cell transplantation with post-transplantation cyclophosphamide in patients with primary immunodeficiency diseases. Biol Blood Marrow Transplant. 2020;26(10):1923\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3389_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaci.2019.01.030","volume":"144","author":"R Elfeky","year":"2019","unstructured":"Elfeky R, Shah RM, Unni MNM, Ottaviano G, Rao K, Chiesa R, et al. New graft manipulation strategies improve the outcome of mismatched stem cell transplantation in children with primary immunodeficiencies. J Allergy Clin Immunol. 2019;144(1):280\u201393.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"3389_CR31","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.bbmt.2015.07.008","volume":"21","author":"D Balashov","year":"2015","unstructured":"Balashov D, Shcherbina A, Maschan M, Trakhtman P, Skvortsova Y, Shelikhova L, et al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCR\u03b1\u03b2 and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transplant. 2015;21(11):1955\u201362.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"3389_CR32","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jaci.2017.07.008","volume":"141","author":"RM Shah","year":"2018","unstructured":"Shah RM, Elfeky R, Nademi Z, Qasim W, Amrolia P, Chiesa R, et al. T-cell receptor \u03b1\u03b2+ and CD19+ cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immunol. 2018;141(4):1417-1426.e1.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3389_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13517","volume":"23","author":"R Mitchell","year":"2019","unstructured":"Mitchell R, Cole T, Shaw PJ, Mechinaud F, O\u2019Brien T, Fraser C. TCR \u03b1+\u03b2+\/CD19+ cell-depleted hematopoietic stem cell transplantation for pediatric patients. Pediatr Transplant. 2019;23(6): e13517.","journal-title":"Pediatr Transplant"},{"issue":"2","key":"3389_CR34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190607","volume":"217","author":"A Fischer","year":"2020","unstructured":"Fischer A, Hacein-Bey-Abina S. Gene therapy for severe combined immunodeficiencies and beyond. J Exp Med. 2020;217(2): e20190607.","journal-title":"J Exp Med"},{"issue":"17","key":"3389_CR35","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/blood-2011-12-396879","volume":"120","author":"A Hassan","year":"2012","unstructured":"Hassan A, Booth C, Brightwell A, Allwood Z, Veys P, Rao K, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17):3615\u201324 (quiz 3626).","journal-title":"Blood"},{"issue":"4","key":"3389_CR36","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/bjh.15831","volume":"185","author":"E Rivers","year":"2019","unstructured":"Rivers E, Worth A, Thrasher AJ, Burns SO. How I manage patients with Wiskott Aldrich syndrome. Br J Haematol. 2019;185(4):647\u201355.","journal-title":"Br J Haematol"},{"key":"3389_CR37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2147\/JBM.S232650","volume":"12","author":"KK Mallhi","year":"2021","unstructured":"Mallhi KK, Petrovic A, Ochs HD. Hematopoietic stem cell therapy for Wiskott\u2013Aldrich syndrome: improved outcome and quality of life. J Blood Med. 2021;12:435\u201347.","journal-title":"J Blood Med"},{"issue":"2","key":"3389_CR38","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood-2003-05-1480","volume":"103","author":"K Imai","year":"2004","unstructured":"Imai K, Morio T, Zhu Y, Jin Y, Itoh S, Kajiwara M, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103(2):456\u201364.","journal-title":"Blood"},{"issue":"7583","key":"3389_CR39","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/S0140-6736(68)92672-X","volume":"292","author":"FH Bach","year":"1968","unstructured":"Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone-marrow transplantation in a patient with the Wiskott\u2013Aldrich syndrome. Lancet. 1968;292(7583):1364\u20136.","journal-title":"Lancet"},{"issue":"3","key":"3389_CR40","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12185-019-02686-y","volume":"110","author":"A Iguchi","year":"2019","unstructured":"Iguchi A, Cho Y, Yabe H, Kato S, Kato K, Hara J, et al. Long-term outcome and chimerism in patients with Wiskott\u2013Aldrich syndrome treated by hematopoietic cell transplantation: a retrospective nationwide survey. Int J Hematol. 2019;110(3):364\u20139.","journal-title":"Int J Hematol"},{"issue":"23","key":"3389_CR41","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood.2019002939","volume":"135","author":"LM Burroughs","year":"2020","unstructured":"Burroughs LM, Petrovic A, Brazauskas R, Liu X, Griffith LM, Ochs HD, et al. Excellent outcomes following hematopoietic cell transplantation for Wiskott\u2013Aldrich syndrome: a PIDTC report. Blood. 2020;135(23):2094\u2013105.","journal-title":"Blood"},{"issue":"6","key":"3389_CR42","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","volume":"118","author":"D Moratto","year":"2011","unstructured":"Moratto D, Giliani S, Bonfim C, Mazzolari E, Fischer A, Ochs HD, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott\u2013Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980\u20132009: an international collaborative study. Blood. 2011;118(6):1675\u201384.","journal-title":"Blood"},{"issue":"8","key":"3389_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27092","volume":"65","author":"Y Yue","year":"2018","unstructured":"Yue Y, Shi X, Song Z, Qin J, Li J, Feng S, et al. Posttransplant cyclophosphamide for haploidentical stem cell transplantation in children with Wiskott\u2013Aldrich syndrome. Pediatr Blood Cancer. 2018;65(8): e27092.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"3389_CR44","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.bbmt.2018.03.006","volume":"24","author":"D Balashov","year":"2018","unstructured":"Balashov D, Laberko A, Shcherbina A, Trakhtman P, Abramov D, Gutovskaya E, et al. A conditioning regimen with plerixafor is safe and improves the outcome of TCR\u03b1\u03b2+ and CD19+ cell-depleted stem cell transplantation in patients with Wiskott\u2013Aldrich syndrome. Biol Blood Marrow Transplant. 2018;24(7):1432\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"3389_CR45","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jaci.2014.04.041","volume":"134","author":"G Kharya","year":"2014","unstructured":"Kharya G, Nademi Z, Leahy TR, Dunn J, Barge D, Schulz A, et al. Haploidentical T-cell alpha beta receptor and CD19-depleted stem cell transplant for Wiskott\u2013Aldrich syndrome. J Allergy Clin Immunol. 2014;134(5):1199\u2013201.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3389_CR46","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jaci.2020.06.018","volume":"146","author":"F Ferrua","year":"2020","unstructured":"Ferrua F, Marangoni F, Aiuti A, Roncarolo MG. Gene therapy for Wiskott\u2013Aldrich syndrome: history, new vectors, future directions. J Allergy Clin Immunol. 2020;146(2):262\u20135.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3389_CR47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41591-021-01641-x","volume":"28","author":"A Magnani","year":"2022","unstructured":"Magnani A, Semeraro M, Adam F, Booth C, Dupr\u00e9 L, Morris EC, et al. Long-term safety and efficacy of lentiviral hematopoietic stem\/progenitor cell gene therapy for Wiskott\u2013Aldrich syndrome. Nat Med. 2022;28(1):71\u201380.","journal-title":"Nat Med"},{"issue":"16","key":"3389_CR48","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1182\/blood.2019000936","volume":"135","author":"SW Canna","year":"2020","unstructured":"Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135(16):1332\u201343.","journal-title":"Blood"},{"issue":"1","key":"3389_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","volume":"40","author":"SG Tangye","year":"2020","unstructured":"Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24\u201364.","journal-title":"J Clin Immunol"},{"issue":"2","key":"3389_CR50","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0022-3476(86)81002-2","volume":"108","author":"A Fischer","year":"1986","unstructured":"Fischer A, Cerf-Bensussan N, Blanche S, Deist FL, Bremard-Oury C, Leverger G, et al. Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J Pediatr. 1986;108(2):267\u201370.","journal-title":"J Pediatr"},{"issue":"3","key":"3389_CR51","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaci.2021.07.031","volume":"149","author":"RA Marsh","year":"2022","unstructured":"Marsh RA, Hebert K, Kim S, Dvorak CC, Aquino V, Baker KS, et al. Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders. J Allergy Clin Immunol. 2022;149(3):1097-1104.e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"25","key":"3389_CR52","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten E, Horne A, Aric\u00f3 M, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728\u201338.","journal-title":"Blood"},{"issue":"7","key":"3389_CR53","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","volume":"100","author":"J-I Henter","year":"2002","unstructured":"Henter J-I, Samuelsson-Horne A, Aric\u00f2 M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367\u201373.","journal-title":"Blood"},{"issue":"17","key":"3389_CR54","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","volume":"118","author":"H Trottestam","year":"2011","unstructured":"Trottestam H, Horne A, Aric\u00f2 M, Egeler RM, Filipovich AH, Gadner H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577\u201384.","journal-title":"Blood"},{"issue":"2","key":"3389_CR55","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/pbc.22310","volume":"54","author":"S Ohga","year":"2010","unstructured":"Ohga S, Kudo K, Ishii E, Honjo S, Morimoto A, Osugi Y, et al. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein\u2013Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer. 2010;54(2):299\u2013306.","journal-title":"Pediatr Blood Cancer"},{"issue":"26","key":"3389_CR56","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1182\/blood-2010-04-282392","volume":"116","author":"RA Marsh","year":"2010","unstructured":"Marsh RA, Vaughn G, Kim M-O, Li D, Jodele S, Joshi S, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116(26):5824\u201331.","journal-title":"Blood"},{"issue":"3","key":"3389_CR57","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1182\/blood-2005-05-1819","volume":"107","author":"N Cooper","year":"2006","unstructured":"Cooper N, Rao K, Gilmour K, Hadad L, Adams S, Cale C, et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood. 2006;107(3):1233\u20136.","journal-title":"Blood"},{"issue":"25","key":"3389_CR58","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1182\/blood-2015-12-684498","volume":"127","author":"B Hartz","year":"2016","unstructured":"Hartz B, Marsh R, Rao K, Henter J-I, Jordan M, Filipovich L, et al. The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood. 2016;127(25):3281\u201390.","journal-title":"Blood"},{"issue":"3","key":"3389_CR59","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5045\/br.2015.50.3.131","volume":"50","author":"JJ Seo","year":"2015","unstructured":"Seo JJ. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: recent advances and controversies. Blood Res. 2015;50(3):131\u20139.","journal-title":"Blood Res"},{"issue":"1","key":"3389_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2010-06-284935","volume":"117","author":"C Booth","year":"2011","unstructured":"Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, et al. X-linked lymphoproliferative disease due to SAP\/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117(1):53\u201362.","journal-title":"Blood"},{"issue":"10","key":"3389_CR61","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.bbmt.2014.06.003","volume":"20","author":"RA Marsh","year":"2014","unstructured":"Marsh RA, Bleesing JJ, Chandrakasan S, Jordan MB, Davies SM, Filipovich AH. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency\/X-linked lymphoproliferative disease type 1. Biol Blood Marrow Transplant. 2014;20(10):1641\u20135.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"3389_CR62","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1399-3038.2012.01282.x","volume":"23","author":"H Kanegane","year":"2012","unstructured":"Kanegane H, Yang X, Zhao M, Yamato K, Inoue M, Hamamoto K, et al. Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis. Pediatr Allergy Immunol. 2012;23(5):488\u201393.","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"3389_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10875-016-0348-4","volume":"37","author":"S Ono","year":"2017","unstructured":"Ono S, Okano T, Hoshino A, Yanagimachi M, Hamamoto K, Nakazawa Y, et al. Hematopoietic stem cell transplantation for XIAP deficiency in Japan. J Clin Immunol. 2017;37(1):85\u201391.","journal-title":"J Clin Immunol"},{"issue":"1","key":"3389_CR64","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10875-021-01103-6","volume":"42","author":"DE Arnold","year":"2022","unstructured":"Arnold DE, Nofal R, Wakefield C, Lehmberg K, Wustrau K, Albert MH, et al. Reduced-intensity\/reduced-toxicity conditioning approaches are tolerated in XIAP deficiency but patients fare poorly with acute GVHD. J Clin Immunol. 2022;42(1):36\u201345.","journal-title":"J Clin Immunol"},{"issue":"6","key":"3389_CR65","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2012-06-432500","volume":"121","author":"RA Marsh","year":"2013","unstructured":"Marsh RA, Rao K, Satwani P, Lehmberg K, M\u00fcller I, Li D, et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood. 2013;121(6):877\u201383.","journal-title":"Blood"},{"issue":"2","key":"3389_CR66","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/petr.12626","volume":"20","author":"K Umeda","year":"2015","unstructured":"Umeda K, Adachi S, Horikoshi Y, Imai K, Terui K, Endo M, et al. Allogeneic hematopoietic stem cell transplantation for Chediak\u2013Higashi syndrome. Pediatr Transplant. 2015;20(2):271\u20135.","journal-title":"Pediatr Transplant"},{"issue":"7","key":"3389_CR67","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/sj.bmt.1705600","volume":"39","author":"M Eapen","year":"2007","unstructured":"Eapen M, DeLaat CA, Baker KS, Cairo MS, Cowan MJ, Kurtzberg J, et al. Hematopoietic cell transplantation for Chediak\u2013Higashi syndrome. Bone Marrow Transplant. 2007;39(7):411\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"3389_CR68","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/pbc.24637","volume":"60","author":"K Nagai","year":"2013","unstructured":"Nagai K, Ochi F, Terui K, Maeda M, Ohga S, Kanegane H, et al. Clinical characteristics and outcomes of Ch\u00e9diak\u2013Higashi syndrome: a nationwide survey of Japan. Pediatr Blood Cancer. 2013;60(10):1582\u20136.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"3389_CR69","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1038\/s41409-020-0885-6","volume":"55","author":"M Al-Mofareh","year":"2020","unstructured":"Al-Mofareh M, Ayas M, Al-Seraihy A, Siddiqui K, Al-Jefri A, Ghemlas I, et al. Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: a single-center report on 35 patients. Bone Marrow Transplant. 2020;55(10):2026\u201334.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"3389_CR70","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood-2009-02-207845","volume":"114","author":"JP Schmid","year":"2009","unstructured":"Schmid JP, Moshous D, Boddaert N, Neven B, Cortivo LD, Tardieu M, et al. Hematopoietic stem cell transplantation in Griscelli syndrome type 2: a single-center report on 10 patients. Blood. 2009;114(1):211\u20138.","journal-title":"Blood"},{"issue":"7","key":"3389_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13040","volume":"21","author":"B Kuskonmaz","year":"2017","unstructured":"Kuskonmaz B, Ayvaz D, Gokce M, Ozgur TT, Okur FV, Cetin M, et al. Hematopoietic stem cell transplantation in children with Griscelli syndrome: a single-center experience. Pediatr Transplant. 2017;21(7): e13040.","journal-title":"Pediatr Transplant"},{"issue":"5","key":"3389_CR72","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/petr.12092","volume":"17","author":"AA Hamidieh","year":"2013","unstructured":"Hamidieh AA, Pourpak Z, Yari K, Fazlollahi MR, Hashemi S, Behfar M, et al. Hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen in pediatric patients with Griscelli syndrome type 2. Pediatr Transplant. 2013;17(5):487\u201391.","journal-title":"Pediatr Transplant"},{"issue":"1","key":"3389_CR73","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/bmb\/ldw009","volume":"118","author":"D Roos","year":"2016","unstructured":"Roos D. Chronic granulomatous disease. Br Med Bull. 2016;118(1):50\u201363.","journal-title":"Br Med Bull"},{"issue":"2","key":"3389_CR74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12016-020-08800-x","volume":"61","author":"H-H Yu","year":"2021","unstructured":"Yu H-H, Yang Y-H, Chiang B-L. Chronic granulomatous disease: a comprehensive review. Clin Rev Allerg Immunol. 2021;61(2):101\u201313.","journal-title":"Clin Rev Allerg Immunol"},{"key":"3389_CR75","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.3389\/fimmu.2020.01617","volume":"11","author":"M Yanagimachi","year":"2020","unstructured":"Yanagimachi M, Kato K, Iguchi A, Sasaki K, Kiyotani C, Koh K, et al. Hematopoietic cell transplantation for chronic granulomatous disease in Japan. Front Immunol. 2020;11:2600\u20139.","journal-title":"Front Immunol"},{"issue":"10","key":"3389_CR76","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood.2020005590","volume":"136","author":"R Chiesa","year":"2020","unstructured":"Chiesa R, Wang J, Blok H-J, Hazelaar S, Neven B, Moshous D, et al. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood. 2020;136(10):1201\u201311.","journal-title":"Blood"},{"issue":"4","key":"3389_CR77","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s10875-019-00635-2","volume":"39","author":"JR Yonkof","year":"2019","unstructured":"Yonkof JR, Gupta A, Fu P, Garabedian E, Dalal J, Consortium and the USIN. Role of allogeneic hematopoietic stem cell transplant for chronic granulomatous disease (CGD): a report of the United States Immunodeficiency Network. J Clin Immunol. 2019;39(4):448\u201358.","journal-title":"J Clin Immunol"},{"issue":"5","key":"3389_CR78","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaci.2013.05.031","volume":"132","author":"T Cole","year":"2013","unstructured":"Cole T, Pearce MS, Cant AJ, Cale CM, Goldblatt D, Gennery AR. Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013;132(5):1150\u20135.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3389_CR79","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/pai.13402","volume":"32","author":"C Dedieu","year":"2021","unstructured":"Dedieu C, Albert MH, Mahlaoui N, Hauck F, Hedrich C, Baumann U, et al. Outcome of chronic granulomatous disease\u2014conventional treatment vs stem cell transplantation. Pediatr Allergy Immunol. 2021;32(3):576\u201385.","journal-title":"Pediatr Allergy Immunol"},{"issue":"13","key":"3389_CR80","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1182\/blood-2002-02-0583","volume":"100","author":"RA Seger","year":"2002","unstructured":"Seger RA, Gungor T, Belohradsky BH, Blanche S, Bordigoni P, Bartolomeo PD, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985\u20132000. Blood. 2002;100(13):4344\u201350.","journal-title":"Blood"},{"issue":"9915","key":"3389_CR81","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","volume":"383","author":"T G\u00fcng\u00f6r","year":"2014","unstructured":"G\u00fcng\u00f6r T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436\u201348.","journal-title":"Lancet"},{"issue":"1","key":"3389_CR82","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41409-018-0271-9","volume":"54","author":"T Osumi","year":"2019","unstructured":"Osumi T, Tomizawa D, Kawai T, Sako M, Inoue E, Takimoto T, et al. A prospective study of allogeneic transplantation from unrelated donors for chronic granulomatous disease with target busulfan-based reduced-intensity conditioning. Bone Marrow Transplant. 2019;54(1):168\u201372.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"3389_CR83","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2016-03-704015","volume":"128","author":"B Morillo-Gutierrez","year":"2016","unstructured":"Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins A-M, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128(3):440\u20138.","journal-title":"Blood"},{"issue":"7","key":"3389_CR84","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.bbmt.2019.03.009","volume":"25","author":"B Neven","year":"2019","unstructured":"Neven B, Diana J-S, Castelle M, Magnani A, Rosain J, Touzot F, et al. Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children. Biol Blood Marrow Transplant. 2019;25(7):1363\u201373.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"3389_CR85","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1016\/j.bbmt.2020.08.008","volume":"26","author":"T Osumi","year":"2020","unstructured":"Osumi T, Yoshimura S, Sako M, Uchiyama T, Ishikawa T, Kawai T, et al. Prospective study of allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide and antithymocyte globulin from HLA-mismatched related donors for nonmalignant diseases. Biol Blood Marrow Transplant. 2020;26(11):e286\u201391.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03389-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03389-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03389-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T17:42:13Z","timestamp":1656006133000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03389-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["3389"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03389-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}